The new strain Lactobacillus pentosus CECT 7504 (i.e. BCRC 910650) is provided. The strain presents as key advantages: a high survival to the antimicrobial factors found in vaginal fluid, factors that are often increased in a subset of patients with candidiasis, and that could be very harmful to many probiotics； the capacity to inhibit Candida albicans and Candida glabrata, thus displaying a broader spectrum activity to help manage Candida infections such as vulvovaginal candidiasis； the capacity to survive against high concentrations of antimycotic agents typically used to manage Candida infections, thus allowing its co-administration； and an improved capacity to acidify vaginal fluid, thus displaying a high potential to help manage bacterial vaginosis. Therefore, the strain and products comprising it are useful in the prevention and/or treatment of candidiasis (oral, intestinal and vaginal) and of bacterial vaginosis.提供新菌株戊糖乳桿菌CECT 7504(即BCRC 910650)。所述菌株呈現以下作為關鍵優點：在陰道液中發現之抗微生物因子下高度存活，所述因子在念珠菌病患者子集中時常增加且可對許多益生菌非常有害；能夠抑制白色念珠菌及光滑念珠菌，因此顯示更廣泛活性以幫助處理念珠菌屬感染，諸如外陰陰道念珠菌病；針對通常用以處理念珠菌屬感染之高濃度抗黴菌劑能夠存活，因此允許其共同投與；及酸化陰道液之能力提高，因此顯示幫助處理細菌性陰道炎之高潛能。因此，菌株及包括其之產品適用於預防及/或治療念珠菌病(口腔、腸及陰道)及細菌性陰道炎。
